Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: SPECTRALIS Clear all
Terminated No phase listed Observational Accepts healthy volunteers

Evaluation of the Repeatability and Reproducibility of OCTA Image Quality With the Heidelberg Engineering SPECTRALIS With OCT Angiography Module

NCT03530449
View directory record Official record
Conditions
Retinal Vascular, Normal Eyes
Interventions
OCT Angiography, Color Fundus Photography, Optical Coherence Tomography
Device
Lead sponsor
Heidelberg Engineering GmbH
Industry
Eligibility
22 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Sep 5, 2026, 5:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Atlas of Retinal Imaging in Alzheimer's Study

NCT03862222
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia, Aging, Cognitive Change
Interventions
Retinal Imaging, Pupillometry, Contrast Sensitivity, Neuropsychological Evaluation, APOE genotyping, blood draw, Gait Assessment, Actigraphy
Other · Diagnostic Test · Genetic
Lead sponsor
University of Rhode Island
Other
Eligibility
55 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
4
States / cities
Clearwater, Florida • St. Petersburg, Florida • Kingston, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 5, 2026, 5:44 PM EDT
Completed Not applicable Interventional

Evaluating Home Testing Devices for the Management of Glaucoma

NCT05325996
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Standard Automatic Perimetry Humphrey Field Analyzer, visuALL H, iCare Home Tonometer, Spectralis Optical coherence tomography (OCT)
Diagnostic Test
Lead sponsor
Wills Eye
Other
Eligibility
20 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 5, 2026, 5:44 PM EDT
Terminated Not applicable Interventional Results available

Anterior-segment OCT (AS-OCT) and Intraoperative OCT (iOCT) for Trans- Conjunctival Needle Revision (TCNR)

NCT05790408
View directory record Official record
Conditions
Glaucoma, Glaucoma Following Surgery
Interventions
Digital microscope integrated with intraoperative OCT (Zeiss Artevo 800, Carl Zeiss Meditec AG), Spectralis Anterior-segment OCT (AS-OCT) (Heidelberg Engineering)
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Sep 5, 2026, 5:44 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion

NCT01827722
View directory record Official record
Conditions
Macular Edema, Central Retinal Vein Occlusion
Interventions
Ozurdex, Ranibizumab, Combination Ozurdex with Ranibizumab PRN
Drug
Lead sponsor
Valley Retina Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
5
States / cities
Beverly Hills, California • Lakeland, Florida • Winter Haven, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 5, 2026, 5:44 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Macular Pigment Measurements in Eye & Other Tissues

NCT03022773
View directory record Official record
Conditions
Macular Pigmentation, Skin Pigment
Interventions
Carotenoid measurements
Other
Lead sponsor
University of Utah
Other
Eligibility
7 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 5, 2026, 5:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Additional Heidelberg Engineering SPECTRALIS With OCT Angiography Module (OCTA Module) Scan Types

NCT04604002
View directory record Official record
Conditions
Retinal Vascular, Normal Eyes
Interventions
OCT Angiography, Color Fundus Photography, Optical Coherence Tomography
Device
Lead sponsor
Heidelberg Engineering GmbH
Industry
Eligibility
22 Years and older
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 5, 2026, 5:44 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Optical Coherence Tomography (OCT) Reference Data Collection Study (S-2015-3)

NCT02785042
View directory record Official record
Conditions
Glaucoma
Interventions
Heidelberg Spectralis OCT
Device
Lead sponsor
Heidelberg Engineering GmbH
Industry
Eligibility
18 Years to 90 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
8
States / cities
La Jolla, California • Santa Monica, California • Santa Rosa, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 5, 2026, 5:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Heidelberg Engineering SPECTRALIS OCT Signal to Noise Ratio Effect on Parameter Measurements

NCT04961398
View directory record Official record
Conditions
Normal Eyes
Interventions
OCT imaging
Device
Lead sponsor
Heidelberg Engineering GmbH
Industry
Eligibility
22 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Franklin, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 5, 2026, 5:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the Heidelberg Engineering SPECTRALIS With Flex Module for In-vivo Imaging in the Supine Position

NCT04661124
View directory record Official record
Conditions
Retinal Disease, Healthy Eyes
Interventions
SPECTRALIS, SPECTRALIS with Flex Module
Device
Lead sponsor
Heidelberg Engineering GmbH
Industry
Eligibility
22 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 5, 2026, 5:44 PM EDT
Completed No phase listed Observational

NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients

NCT03969303
View directory record Official record
Conditions
AMD - Age-Related Macular Degeneration, Diabetic Macular Edema
Interventions
Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5)
Device
Lead sponsor
Notal Vision Ltd.
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Sep 5, 2026, 5:44 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

OCT Angiography and NRAI in Dementia

NCT03761381
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Mild Cognitive Impairment
Interventions
Optical Coherence Tomography Angiography (OCTA) Imaging, Noninvasive Retinal Amyloid Imaging (NRAI)
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 5, 2026, 5:44 PM EDT
Recruiting Not applicable Interventional

COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Inherited Retinal Disease

NCT06380075
View directory record Official record
Conditions
Retinal Disease
Interventions
Spectralis FAF imaging, Optos imaging, Clarus imaging
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 5, 2026, 5:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Heidelberg Engineering SPECTRALIS With OCT Angiography Module

NCT03279939
View directory record Official record
Conditions
Retinal Vascular, Normal Eyes
Interventions
OCT Angiography, Color Fundus Photography, Fluorescein Angiography, Indocyaine Green Angiography
Device
Lead sponsor
Heidelberg Engineering GmbH
Industry
Eligibility
22 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 5, 2026, 5:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Spectralis HRA+OCT Imaging of the Retina With Autofluorescence in Sickle Cell Disease

NCT01123369
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Medical University of South Carolina
Other
Eligibility
12 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Sep 5, 2026, 5:44 PM EDT
Recruiting Not applicable Interventional

A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors

NCT07449195
View directory record Official record
Conditions
Ocular Tumor
Interventions
Intalight Dream OCT, Heidelberg Spectralis OCT
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 5, 2026, 5:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Optical Coherence Tomography (OCT) Normative Data Collection Study

NCT02014688
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Heidelberg Engineering GmbH
Industry
Eligibility
18 Years to 90 Years
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Sep 5, 2026, 5:44 PM EDT
Enrolling by invitation Not applicable Interventional

Adaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study

NCT07747662
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Adaptive Optics Scanning Light Ophthalmoscopy, Microperimetry, Optical Coherence Tomography
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 5, 2026, 5:44 PM EDT
Completed Not applicable Interventional Results available

COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy

NCT05961332
View directory record Official record
Conditions
Macular Degeneration, Age Related, Geographic Atrophy
Interventions
Spectralis FAF imaging, Optos imaging, Zeiss Clarus 700 imaging
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 5, 2026, 5:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Heidelberg Engineering SPECTRALIS Macular Precision and Agreement Study

NCT03903588
View directory record Official record
Conditions
Retinal Layer Separation
Interventions
Optical Coherence Tomography
Device
Lead sponsor
Heidelberg Engineering GmbH
Industry
Eligibility
22 Years and older
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 5, 2026, 5:44 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

NCT04008121
View directory record Official record
Conditions
Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration
Interventions
Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system, MB-102 and commercially available optical angiography imaging system
Combination Product
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 5, 2026, 5:44 PM EDT